These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 23093355)

  • 21. Radioembolization for the treatment of hepatocellular carcinoma.
    Kim HC
    Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study.
    Yu Q; Thapa N; Karani K; Navuluri R; Ahmed O; Van Ha T
    J Vasc Interv Radiol; 2022 Dec; 33(12):1570-1577.e1. PubMed ID: 36100064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.
    Zori AG; Ismael MN; Limaye AR; Firpi R; Morelli G; Soldevila-Pico C; Suman A; Vogel JD; Lazarowicz M; Geller BS; Toskich B; Gonzalo DH; Johnson MW; Cabrera R
    Am J Clin Oncol; 2020 May; 43(5):325-333. PubMed ID: 32079854
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
    Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Chemoembolization, Radioembolization, and Transarterial Ethanol Ablation for Huge Hepatocellular Carcinoma (≥ 10 cm) in Tumour Response and Long-Term Survival Outcome.
    Yu SCH; Hui JW; Li L; Cho CC; Hui EP; Chan SL; Yeo WM
    Cardiovasc Intervent Radiol; 2022 Feb; 45(2):172-181. PubMed ID: 34604920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
    Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
    Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of Blood Pressure Changes in the Vascular Compartment When Using an Anti-Reflux Catheter during Chemoembolization versus Radioembolization: A Retrospective Case Series.
    Rose SC; Narsinh KH; Newton IG
    J Vasc Interv Radiol; 2017 Jan; 28(1):103-110. PubMed ID: 27840042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.
    Somma F; Stoia V; Serra N; D'Angelo R; Gatta G; Fiore F
    PLoS One; 2019; 14(5):e0216935. PubMed ID: 31141552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.
    Rognoni C; Ciani O; Sommariva S; Facciorusso A; Tarricone R; Bhoori S; Mazzaferro V
    Oncotarget; 2016 Nov; 7(44):72343-72355. PubMed ID: 27579537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated With Complete Pathologic Necrosis of Hepatocellular Carcinoma on Explant Evaluation After Locoregional Therapy: A National Analysis Using the UNOS Database.
    Sarwar A; Bonder A; Hassan L; Malik MS; Novack V; Curry M; Ahmed M
    AJR Am J Roentgenol; 2023 May; 220(5):727-735. PubMed ID: 36475810
    [No Abstract]   [Full Text] [Related]  

  • 35. Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries.
    Sanoff HK; Chang Y; Stavas JM; Stürmer T; Lund J
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1102-10. PubMed ID: 26358794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of dynamic hepatobiliary contrast-enhanced MRI signal intensity after Yttrium-90 radioembolization with glass microspheres for the treatment of hepatocellular carcinoma.
    Syed M; Shah J; Montazeri SA; Grajo JR; Geller B; Toskich B
    Abdom Radiol (NY); 2021 May; 46(5):2182-2187. PubMed ID: 33216180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Previous Transarterial Chemoembolization on Survival and Toxicity after Yttrium-90 Transarterial Radioembolization of Hepatocellular Carcinoma in the Radiation-Emitting SIR-Spheres in Nonresectable Liver Tumor Registry.
    Hund HC; Du L; Matsuoka L; Sze DY; Kennedy AS; Golzarian J; Gandhi RT; Collins ZS; Brown DB
    J Vasc Interv Radiol; 2023 Dec; 34(12):2147-2154.e2. PubMed ID: 37657500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.
    Lau WY; Sangro B; Chen PJ; Cheng SQ; Chow P; Lee RC; Leung T; Han KH; Poon RT
    Oncology; 2013; 84(5):311-8. PubMed ID: 23615394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
    Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.